Elixir Medical Corp.

Related Content

News
Coronary Bioadaptor Systems Demonstrates Significant Improvement for Patients with ACS, Complex Lesion Subsets

Oct. 28, 2024 – Elixir Medical today announced late-breaking data demonstrating significant benefit of the DynamX ...

Home October 29, 2024
arrow
Primary endpoint, six-month clinical and imaging data from clinical trial of DESyne BDS Plus stent system evaluating safety and efficacy of localized delivery of anticoagulants and an anti-proliferative agent designed to reduce the implant thrombotic risk
News | Stents Drug Eluting
Elixir Medical To Present Randomized Clinical Dataset Featuring World’s First Triple Drug-Eluting Coronary Implant Eluting Two Anticoagulants and Sirolimus at TCT 2023

October 10, 2023 — Elixir Medical, a developer of innovative cardiovascular technologies, announced it will present ...

Home October 10, 2023
arrow
Largest randomized trial of DynamX Bioadaptor to date with 2,400 patients enrolled, covering real-world population
News | Stents Drug Eluting
Elixir Medical Completes Enrollment of INFINITY-SWEDEHEART Clinical Trial

July 13, 2023 — Elixir Medical, a developer of breakthrough cardiovascular technologies, announced enrollment completion ...

Home July 13, 2023
arrow
Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, has announced completion of enrollment in the BIOADAPTOR randomized controlled trial (RCT). The BIOADAPTOR RCT is evaluating the DynamX Coronary Bioadaptor System,
News | Stents Drug Eluting
Elixir Medical Completes Enrollment in Bioadaptor Randomized Controlled Trial of DynamX Coronary Bioadaptor System

February 16, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, has announced ...

Home February 16, 2022
arrow
The Elixer Dynamx Coronary Bioadaptor Stent technology uses a bioresorbable polymer that dissolves after three months and disconnected joints between numerous stent segments, allowing it to articulate and share to the vessel and movement.
News | Stents
First Patient Treated in Elixer Dynamx Coronary Bioadaptor Stent Technology

April, 14, 2021 – Elixir Medical recently announced the first patient was treated in the BIOADAPTOR randomized ...

Home April 14, 2021
arrow
News | Stents Drug Eluting
Elixir Medical Corp. to Unveil DynamX Metallic Stent at TCT 2017

October 25, 2017 — Elixir Medical Corp. announced it will unveil a new metallic drug-eluting stent (DES) platform at ...

Home October 25, 2017
arrow
bioresorbable stents, dissolving stents, Absorb stent, BVS
Feature | Stents Bioresorbable| Dave Fornell
Bioresorbable Stents Are the Way of the Future

(UPDATE: read the Sept. 8, 2017 article "Abbott Will End Sales of Absorb Bioresorbable Stent") A key prediction for ...

Home September 03, 2014
arrow
Elixir Medical Corp. DESolve 100 CE mark
Feature
Elixir Receives European Approval for Fully Bioresorbable Novolimus-eluting Coronary Stent

May 13, 2014 — Elixir Medical Corp. received European CE mark approval for its DESolve 100 Novolimus-eluting ...

Home May 13, 2014
arrow
Elixir Medical DESolve Bioresorbable Coronary Scaffold System Stents
News
Elixir Completes First Commercial Implant Of Fully Bioresorbable Stent

January 22, 2014 — The first commercial implant of Elixir Medical’s CE Mark-approved DESolve Novolimus Eluting Coronary ...

Home January 22, 2014
arrow
Elixer bioresorbable stent
Feature
Elixir Gains European Approval for Fully Bioresorbable Drug-Eluting Coronary Stent

May 16, 2013 — Elixir Medical Corp. announced it received CE (Conformité Européenne) mark approval for its DESolve ...

Home May 16, 2013
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now